WFI
NBIX icon

West Family Investments’s Neurocrine Biosciences NBIX Stock Holding History

West Family Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Buy
+1,923
New +$285K 0.09% 300
2024
Q3 		– Sell
-1,484
Closed -$204K – 300
2024
Q2 		$204K Hold
1,484
– – 0.06% 236
2024
Q1 		$205K Buy
+1,484
New +$203K 0.06% 243

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

West Family Investments's NBIX Position: Q2 2026 in Review

West Family Investments opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,923 shares worth $324K. The stake represents 0.09% of the portfolio and ranks #300 among its holdings. This is a return to the name: West Family Investments previously reported a position in NBIX as recently as Q2 2024.

West Family Investments first reported a position in NBIX in Q1 2024 and has held it in 3 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • West Family Investments held 1,923 shares of Neurocrine Biosciences worth $324K as of Q2 2026.
  • Neurocrine Biosciences was a new West Family Investments position in Q2 2026.
  • Neurocrine Biosciences made up 0.09% of West Family Investments's portfolio in Q2 2026, its #300 holding.
  • West Family Investments first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 3 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on West Family Investments's 13F filing for Q2 2026, filed 10 Aug 2026.